8-K: Harvard Bioscience Faces Nasdaq Delisting Notice and Announces CFO Transition

Harvard Bioscience received a Nasdaq notice regarding minimum bid price non-compliance and announced the resignation of its CFO, Jennifer Cote, with Mark Frost appointed as Interim CFO.

Summary

• Harvard Bioscience received a notification from Nasdaq on April 4, 2025, indicating non-compliance with the minimum bid price requirement of $1.00 per share.
• The company's stock price remained below $1.00 for 30 consecutive business days, from February 21, 2025, to April 3, 2025.
• Harvard Bioscience has until October 1, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
• If compliance is not achieved by October 1, 2025, the company may be eligible to transfer to the Nasdaq Capital Market and seek an additional 180-day compliance period.
• Jennifer Cote resigned as Chief Financial Officer and Treasurer, effective upon the filing of the company's Quarterly Report on Form 10-Q for the period ended March 31, 2025, expected on or before May 12, 2025.
• Mark Frost was appointed as Interim Chief Financial Officer and Treasurer, effective upon Ms. Cote's resignation, with an annual base salary of $320,000.
• Mr. Frost will also be eligible for a $50,000 cash bonus upon the company's repayment of its existing term loan and senior revolving credit facility.
• Mr. Frost will receive an award of 100,000 time-based restricted stock units (RSUs) that will vest in full one year from the effective date, subject to continued employment.

Sentiment

Score: 4

Explanation: The announcement contains negative news regarding Nasdaq compliance and a CFO transition, offset slightly by the appointment of an experienced Interim CFO. The overall sentiment is cautiously negative.

Positives

• Mark Frost brings over 30 years of financial and executive-level management experience to the Interim CFO role.
• The company has a period to regain compliance with Nasdaq listing rules.

Negatives

• Harvard Bioscience is not in compliance with Nasdaq's minimum bid price requirement, potentially leading to delisting.
• The company is experiencing a CFO transition.

Risks

• Failure to regain compliance with Nasdaq Listing Rule 5450(a)(1) by October 1, 2025, could lead to delisting from The Nasdaq Global Market.
• The company's ability to refinance its outstanding indebtedness is uncertain.
• The company operates in a challenging market environment.

Future Outlook

The company must regain compliance with Nasdaq's minimum bid price rule by October 1, 2025, or face potential delisting. They may seek to transfer to the Nasdaq Capital Market for an additional compliance period.

Management Comments

• Jim Green, Chairman and CEO, expressed confidence in Mark Frost's financial and business acumen.
• Jim Green thanked Jen Cote for her contributions to the company.

Industry Context

The life science tools and services industry is competitive, and Harvard Bioscience faces challenges in maintaining its market position. The company's financial performance and ability to innovate are crucial for its success.

Comparison to Industry Standards

• Other companies in the life science tools and services industry, such as Agilent Technologies, Thermo Fisher Scientific, and Danaher Corporation, maintain strong financial performance and compliance with listing requirements.
• Harvard Bioscience's current non-compliance with Nasdaq's minimum bid price rule places it at a disadvantage compared to its peers.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the potential delisting from The Nasdaq Global Market.
• Employees may experience uncertainty during the CFO transition.
• Customers and suppliers may be affected by any potential disruptions to the company's operations.

Next Steps

• Harvard Bioscience must take steps to regain compliance with Nasdaq Listing Rule 5450(a)(1) by October 1, 2025.
• The company will file its Quarterly Report on Form 10-Q for the period ended March 31, 2025, on or before May 12, 2025.
• Mark Frost will transition into the role of Interim Chief Financial Officer and Treasurer.

Key Dates

Keywords

Harvard Bioscience, Nasdaq, minimum bid price, delisting, CFO, Jennifer Cote, Mark Frost, Interim CFO, resignation, appointment, compliance, restricted stock units, financial officer